541505-04-8

Basic information

• Product Name: Piperazine, 1-(2-fluoroethyl)- (9CI)
• Synonyms: Piperazine, 1-(2-fluoroethyl)- (9CI);1-(2-Fluoro-ethyl)-piperazine;Piperazine, 1-(2-fluoroethyl)-
• CAS NO: 541505-04-8
• Molecular Formula: C₆H₁₃FN₂
• Molecular Weight: 132.1792232
• EINECS: 200-589-5
• Product Categories: AMINETERTIARY
• Mol File: 541505-04-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Piperazine, 1-(2-fluoroethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-(2-fluoroethyl)- (9CI)(541505-04-8)
• EPA Substance Registry System: Piperazine, 1-(2-fluoroethyl)- (9CI)(541505-04-8)

Safety Data

• Hazardous Substances Data: 541505-04-8(Hazardous Substances Data)

Usage

Uses

1-(2-Fluoroethyl)piperazine is used as a PET radioligand for in vivo visualization of phosphodiesterase 5 (PDE5).

Upstream product

• 762-49-2 2-fluoroethyl bromide 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 184042-58-8 tert-butyl 4-(2-fluoroethyl)piperazine-1-carboxylate 

Downstream Products

• 1008130-04-8 SKI₆₉₆ 
• 1335280-89-1 8-(2-chlorophenyl)-6-[4-(2-fluoroethyl)piperazin-1-yl]-9-(2-methoxyethyl)-2-methylpurine 
• 1353625-19-0 C₂₈H₃₆ClFN₈O₃S 
• 1404536-46-4 [4-(4-butyryl-5-methyl-pyrazol-1-yl)phenyl]-1-{2-[4-(2-fluoroethyl)piperazin-1-yl]-2-oxoethyl}-5-methyl-1H-indole-3-carboxamide hydrochloride 

Relevant articles and documents

Development of Novel 18F-PET Agents for Tumor Hypoxia Imaging

Tumor hypoxia is a major factor responsible for tumor progression, metastasis, invasion, and treatment resistance, leading to low local tumor control and recurrence after radiotherapy in cancers. Here,18F-positron emission tomography (PET) probes are developed for visualizing viable hypoxic cells in biopsies. Pimonidazole derivatives and nitroimidazole-based agents bearing sulfonyl linkers were evaluated. A small-animal PET study showed that the tumor uptake of [18F]-23 [poly(ethylene glycols) (PEG)-sulfonyl linker] of 3.36 ± 0.29%ID/g was significantly higher (P 0.01) than that of [18F]-20 (piperazine-linker tracer, 2.55 ± 0.49%ID/g) at 2 h postinjection in UPPL tumors. The tumor-to-muscle uptake ratio of [18F]-23 (2.46 ± 0.48 at 2 h pi) was well improved compared with that of [18F]-FMISO (1.25 ± 0.14 at 2 h pi). A comparable distribution pattern was observed between ex vivo autoradiography of [18F]-23 and pimonidazole staining of the neighboring slice, indicating that [18F]-23 is a promising PET agent for hypoxia imaging.

Imidazopyridine Kinase Inhibitors

The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.